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Abtract N-linked glycosylation is one of the most abun-
dant modifications of proteins in eukaryotic organisms. In
the central reaction of the pathway, oligosaccharyltransfer-
ase (OST), a multimeric complex located at the membrane
of the endoplasmic reticulum, transfers a preassembled
oligosaccharide to selected asparagine residues within the
consensus sequence asparagine-X-serine/threonine. Due to
the high substrate specificity of OST, alterations in the
biosynthesis of the oligosaccharide substrate result in the
hypoglycosylation of many different proteins and a multi-
tude of symptoms observed in the family of congenital
disorders of glycosylation (CDG) type I. This review covers
our knowledge of human OST and describes enzyme
composition. The Stt3 subunit of OST harbors the catalytic
center of the enzyme, but the function of the other, highly
conserved, subunits are less well defined. Some compo-
nents seem to be involved in the recognition and utilization
of glycosylation sites in specific glycoproteins. Indeed,
mutations in the subunit paralogs N33/Tusc3 and IAP do
not yield the pleiotropic phenotypes typical for CDG type I
but specifically result in nonsyndromic mental retardation,
suggesting that the oxidoreductase activity of these subunits
is required for glycosylation of a subset of proteins essential
for brain development.
Introduction
N-linked glycosylation in the endoplasmic reticulum (ER)
N-linked glycosylation is the most frequent protein modi-
fication of membrane and secretory proteins in eukaryotes,
but it also exists in archaea and bacteria. This essential and
highly conserved process in the endoplasmic reticulum
(ER) of all eukaryotic cells is characterized by the transfer
of a preassembled, uniform oligosaccharide (Glc3Man9Glc
NAc2 in most eukaryotes) from the isoprenoid lipid carrier
dolichol pyrophosphate to the side-chain amide group
nitrogen of an asparagine residue contained in a N-X-S(T)
sequon of the polypeptide substrate, where X can be any
amino acid except proline. The glycosylation reaction is
catalyzed by oligosaccharyltransferase (OST), a hetero-
oligomeric membrane protein complex in animals, plants,
and fungi. In bacteria, archaea, and protozoa, OST is a
monomer corresponding to the catalytic subunit of the
eukaryotic OST and catalyzes the transfer of a highly
defined, lipid-linked oligosaccharide (LLO) donor substrate
to a multitude of peptide acceptor sequences located in
different substrate proteins. Mutations affecting the biosyn-
thesis of the activated Glc3Man9GlcNAc2 oligosaccharide
substrate or the biogenesis of OSTs generally have a
systemic effect in eukaryotes and alter glycosylation of
many different glycoproteins. As a matter of fact, it is the
substrate specificity of OST that translates defects in the
biosynthesis of the oligosaccharide substrate into a general-
ized and multisystemic deficiency observed for the different
forms of human congenital disorders of glycosylation type I
(Freeze and Aebi 2005).
N-linked glycans serve a multitude of functions that can
be divided into two main groups correlating with the
processing and maturation pathway: they affect the folding
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and the sorting of proteins in the ER and, after glycan
remodeling in the Golgi compartment, confer multiple
functions that mediate interactions of the cell or the
organism with its environment. In the ER, N-linked glycans
primarily assist in proper folding of the newly synthesized
polypeptide (Helenius 1994; Paulson 1989). The hydro-
philic nature of the covalently attached glycan alters the
biophysical properties of the polypeptide, can affect the
conformation (Wormald and Dwek 1999) of the unfolded
polypeptide chain, and influences protein folding: N-linked
glycans can direct folding chaperones in the ER and protein
folding catalysts such as the ER thiol oxidoreductase
ERp57 to specific domains of glycoprotein substrates
(Frickel et al. 2002; Parodi 2000; Zapun et al. 1999). In
addition, trimming of the N-linked glycans generates
defined oligosaccharide structures that are interpreted by
the quality control process machinery in the ER, and these
signals direct improperly folded polypeptides or non-
assembled subunits of protein complexes to the export
from the ER back to the cytoplasm and degradation by the
proteasome (Aebi et al. 2010; Helenius and Aebi 2004).
Oligosaccharyltransferase reaction in the ER
Figure 1 shows the overall glycosylation reaction in
eukaryotes catalyzed by OST, i.e., transfer of the dolichyl-
pyrophosphate-linked oligosaccharide to the asparagine of
an asparagine-X-serine or threonine (N-X-S/T) sequon in
the acceptor polypeptide, where X can be any amino acid
residue except proline. Though fully assembled tetradeca-
saccharide Glc3Man9GlcNAc2 is the preferred substrate of
eukaryotic OST, many in vitro studies using OST from dog
pancreas or yeast have shown that truncated, lipid-linked
oligosaccharides such as GlcNAc2 or GlcNAc2Man also
serve as OST substrates, though their binding affinities are
low (Bause et al. 1995; Imperiali and Shannon 1991;
Karaoglu et al. 2001; Sharma et al. 1981; Tai and Imperiali
2001). The minimal glycan substrate of OST that still leads
to an N-glycosidic linkage is the dolichol-linked monosac-
charide Dol-PP-GlcNAc (Tai and Imperiali 2001). Interest-
ingly, the acetamido group of the reducing-end GlcNAc is
an essential substrate property, whereas the presence of the
second GlcNAc enhances binding affinity of the substrate
toward OST but does not affect the glycan transfer rate. It
has therefore been proposed that the acetamido group of
GlcNAc and the catalytic center of OST might form a
hydrogen bond network required for catalysis (Tai and
Imperiali 2001). Alternatively, the acetamido group of
GlcNAc might act as a neighboring group in order to
stabilize an oxonium intermediate that is generated by
cleavage of the phosphate-ester linkage (Wacker et al.
2006). Although the exact reaction mechanism of OST still
needs to be elucidated at the atomic level, the mechanism
most likely involves a nucleophilic attack of the side-chain
amide nitrogen of the asparagine located in the selected N-
X-S/T sequon on the C1 atom of GlcNAc (Bause and
Legler 1981). A mechanism to increase the intrinsically low
nucleophilicity of the amide is currently described by two
contradictory mechanistic models (Bause et al. 1997). In
the first model, the acidity of the amide is increased by
hydrogen bond contacts between the side-chain carbonyl
group of asparagine and the α-NH and β-OH groups of the
hydroxyl amino acid in the glycosylation sequon (Imperiali
et al. 1992). The second model favors “inverted” hydrogen-
bond interactions between the amide NH2 protons as donors
and the β-OH group oxygen of the hydroxyl amino acid
(Bause et al. 1995; Bause and Legler 1981; Bause et al.
1997). Irrespective of the precise reaction mechanism, both
models predict that the N-X-S/T sequon has to adopt a
specific conformation that is not compatible with regular
secondary structure elements of folded proteins. It is
important to note that this does not exclude the possibility
that N-linked glycans are covalently linked to asparagine
residues located in α−helical segments or β-strand ele-
ments of folded glycoproteins. It rather implies that
glycosylation in vivo has to occur at the level of the
unfolded glycoprotein substrate, i.e., before its folding to
the native tertiary structure.
Donor and acceptor substrates
of the oligosaccharyltransferase
Though not directly involved in the catalytic transfer, the
different units of the OST substrates define substrate affinity.
The lipid-linked donor substrate Glc3Man9GlcNAc2 is rec-
ognized by OST with high specificity, primarily determined
by the α-1,2-linked glucose residue at the nonreducing end
of Glc3Man9GlcNAc2. Importantly, addition of this hexose
unit represents the final step in a linear assembly pathway of
the branched oligosaccharide, ensuring the transfer of
completely assembled oligosaccharide to proteins (Burda
and Aebi 1999). Absence of this terminal glucose residue
causes impaired glycan recognition and correlates with a
reduced N-glycosylation site occupancy in glycoprotein
substrates. The result is an overall hypoglycosylation of the
N-glycoproteome (Hulsmeier et al. 2007). In vitro studies
confirmed the lowered binding affinities of incompletely
assembled glycans to OST (Karaoglu et al. 2001).
In contrast to the lipid-linked oligosaccharide donor, the
polypeptide acceptor substrates are less clearly defined. N-
X-T sequons are more frequently used than N-X-S sequons,
and in rare cases, the glycosylation of asparagines in N-X-C
sequons has also been observed (Miletich and Broze 1990;
Titani et al. 1986; Zielinska et al. 2010). Recently, N-
glycosylation was also detected on N-X-V and NG motifs.
(Zielinska et al. 2010). Importantly, the existence of the
870 J Inherit Metab Dis (2011) 34:869–878
latter N-glycosylation sites argues against a direct involve-
ment of the β-hydroxyl group of the N-X-S/T motif in the
catalytic process. The large-scale proteomics study of the
mouse N-glycoproteome allows detailed categorization of
glycoproteins and revealed that glycosylation sites are
preferentially located in surface-exposed loop and turn
regions. Almost half of the glycoproteins detected in mice
contain only one modified glycosylation sequon and 22%
are doubly glycosylated. The rest of the N-glycoproteins
contain three to ten glycan structures, and only 2% of the
entire pool of glycoproteins possesses more than ten
glycans (Zielinska et al. 2010). Glycoprotein expression is
highly tissue-specific, as most glycoproteins were found in
brain tissue and the majority of glycoproteins discovered in
brain tissue were not detected in any other tissues. On the
contrary, the minimal figure of glycoproteins was measured
in heart tissue, and only few glycoproteins were exclusively
present in heart tissue (Zielinska et al. 2010).
OST associates with numerous newly synthesized
polypeptide chains, but no plausible mechanistic model
that defines the site occupancy has been proposed to date.
It has been estimated that 65–75% of the potential
glycosylation sequons present in secretory proteins are
modified (Ben-Dor et al. 2004; Petrescu et al. 2004; Schulz
and Aebi 2009). However, individual glycoproteins may
display site occupancy of 98–100% for all glycosylation
sites (Hulsmeier et al. 2007).
Human oligosaccharyltransferase complex
The human OST complex is composed of seven different
polypeptide chains, the sequences of which are highly
conserved among mammalian species (Fig. 2). Subunits of
human OST share a minimum of 90% pairwise sequence
identity with the respective homolog in mouse, bovine,
canine, rat, and golden hamster OST. Isolation and
proteomic characterization of the canine OST complex
revealed the presence of two additional, most likely loosely
associated, proteins, DC2 and KCP2, that have not yet been
verified in the human OST complex (Shibatani et al. 2005).
However, no functional role of these subunits in the
glycosylation process has been reported.
The heptameric human OST complex (Fig. 2) contains
the subunits ribophorin I (OST1p), ribophorin II (Swp1p),
OST48 (Wbp1p), OST4 (OST4), Stt3-A/Stt3-B (Stt3p),
N33/Tusc3 and IAP (OST3p and OST6p), and DAD1
(OST2p). All of these subunits have homologous proteins
in yeast OST (shown in brackets), and a cryo-EM structure
at 12Å resolution has been reported for this enzyme (Li et
al. 2008). Five of the subunit proteins, namely, OST1p,
Swp1p, Wbp1p, Stt3p, and OST2p, are essential for yeast
viability. Based on our current knowledge, we assume that
there is a functional equivalence of the homologous
subunits between the yeast and the human OST complex,
allowing for a description of human subunit function based
on experiments performed in yeast. In the following, we
describe the different subunits of the mammalian, specifi-
cally the human, OST in more detail.
Stt3
Stt3 is the largest and most conserved polypeptide of the
OST complex (Spirig et al. 1997). Stt3 proteins are the
catalytic subunits of eukaryotic OST complexes (Burda and
Aebi 1999; Kelleher et al. 2003; Nilsson et al. 2003; Yan
Fig.1 Oligosaccharyltransferase
(OST) reaction catalyzed by the
OST complex. Note that the α-
glycosidicphosphodiester ester
bond connecting the C1 atom of
the first GlcNAc of
Glc3Man9GlcNAc2 with the py-
rophosphate attached to dolichol
(dol) is converted to a β-N-
glycosidic bond connecting the
C1 atom of the first GlcNAc
with the side chain nitrogen
atom of asparagines that lie
within a glycosylation sequon
[Asn-X-Ser(Thr)] of the poly-
peptide substrate. The reaction
products are the glycosylated
polypeptide substrate, dolichol
diphosphate, and a proton
(Dempski and Imperiali 2002)
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and Lennarz 2002), and protozoan and bacterial N-linked
glycosylation is carried out by a single membrane protein
homologous to Stt3p (Castro et al. 2006; Hese et al. 2009;
Izquierdo et al. 2009; Nasab et al. 2008; Wacker et al.
2002). All Stt3 proteins share the typical signature of a
hydrophobic, N-terminal, membrane-embedded part with
11 or 13 predicted transmembrane helices and a soluble C-
terminal domain that is located in the lumen of the ER in
eukaryotes or in the periplasm of Gram-negative bacteria
(Kelleher and Gilmore 2006). Mammalian genomes encode
two Stt3 isoforms, and either Stt3-A or Stt3-B is incorpo-
rated into the mammalian complex (Kelleher et al. 2003).
The human variants Stt-3A and Stt3-B share 59% amino
acid sequence identity. The larger polypeptide, Stt3-B,
consists of 826 residues whereof the first 558 are predicted
to form the transmembrane domain with 11 or 13
transmembrane helices. The slightly smaller isoform Stt3-
A contains 705 residues and the same predicted membrane
topology. Its transmembrane domain has 11 or 13 predicted
transmembrane helices, followed by an approximately 230-
residue C-terminal domain residing in the ER lumen. Both
Stt3 variants are coexpressed in various tissues but differ in
expression levels. Stt3-A expression was suggested to be
more tissue specific, as high expression levels were
observed in muscle, liver, heart, placenta and pancreas
and very low expression in brain, lung, and kidney. On the
contrary, Stt3-B expression patterns were more even in all
tissues tested (Kelleher et al. 2003).
Canine OST isoforms harboring the different Stt3
proteins differ in catalytic activity and substrate selectivity.
OST complexes with the Stt3-B isoform are more active;
they reach 8- to 12-fold higher Vmax values for glycopep-
tide formation than complexes containingStt3-A (Kelleher
et al. 2003). The increased catalytic activity for Stt3-B
complexes coincides with a reduced selectivity with respect
to the oligosaccharide donor substrate. OST complexes
with Stt3-B accepted the dolichol-pyrophosphate-activated
Glc3Man9GlcNAc2 and Man9GlcNAc2 substrates with
roughly the same specificity, whereas OST complexes
with Stt3-A were more selective, as reflected by increased
Km values forMan9GlcNAc2 relative to Glc3Man9Glc
NAc2(Kelleher et al. 2003). Similar results were obtained
for the human OST complexes isolated from HeLa cells:
OST complexes containing Stt3-B were also found to be
more active than OST complexes harboring Stt3-A (Ruiz-
Canada et al. 2009).
Stt3-A and Stt3-B also differ in their acceptor substrate
selectivity (Wilson and High 2007).The glycosylation state
of different membrane proteins was analyzed in Stt3-A- or
Stt3-B-deficient HeLa cells using specific small interfering
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12 kDa
OST48
46 kDa
Ribophorin II
67 kDa
OST4
4.2 kDaSTT3A /B
81 kDa/94 kDa
N
C
N
C
C
N
CN
N
C
lumen
cytosol
N
Fig. 2 Human oligosaccharyltransferase (OST) complex consists of
equimolar amounts of seven different subunits. There are two isoforms
of the catalytic subunit (Stt3A and Stt3B) and two isoforms of the
subunit with a redox-active, thioredoxin-like domain oriented toward
the endoplasmic reticulum (ER) lumen (N33/Tusc3 and IAP), where
only one of the respective subunits can be incorporated into the OST
complex. Consequently, there are four different variants of the human
OST complex, bearing the subunit pairs Stt3A/(N33/Tusc3), Stt3B/
(N33/Tusc3), Stt3A/IAP, or Stt3B/IAP. The scheme depicts the
membrane topology of the individual subunits [amino (N) and
carboxyl (C) termini] and the number of predicted transmembrane
helices for each subunit. The only parts of the OST complex for which
three-dimensional structure information is available to date are
represented by a ribbon. Specifically, these are: (i) the crystal structure
of the homologue of the luminal domain of Stt3 from Pyrococcus
furiosus, (Igura et al. 2008), (ii) the X-ray structure of the
homologueof the thioredoxin-like domain of N33/Tusc3 from yeast
(OST6) (Schulz et al. 2009) containing the active-site motif CXXC
(depicted in yellow), and (iii) the NMR structure of the yeast
homologue of the smallest subunit OST4 (Zubkov et al. 2004). In
the human OST complex, the ER luminal parts of the subunits
ribophorin I, ribophorin II, Stt3A, and Stt3B are also glycosylation
substrates, with one glycosylation site each in ribophorin I and
ribophorin II, three in Stt3A, and two in Stt3B (Chen et al. 2009). The
molecular masses (in kDa) of the mature, unglycoslyated subunits are
indicated
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RNA (siRNA)-mediated knockdown experiments. Stt3-B
depletion led to hypoglycosylation of certain membrane
proteins. In contrast, a similar approach targeting Stt3-A
resulted in complete loss of both isoforms and abrogation
of glycosylation (Wilson and High 2007). Divergent results
for the specific depletion of the Stt3 isoforms were
observed in a more recent study (Ruiz-Canada et al.
2009). Here, siRNA depletion of Stt3-A resulted in elevated
Stt3-B levels, and conversely, the loss of Stt3-B caused
slightly increased levels of Stt3-A. Both regimes decreased
ribophorin I levels. Endogenous glycoprotein prosaposin
(pSAP) displayed severe hypoglycosylation in the absence
of Stt3-A, but Stt3-B depletion had no effect on the
glycosylation state of this protein. On the other hand,
procathepsin C (pCatC) glycosylation was hardly affected
by Stt3-A deficiency, but the loss of Stt3-B resulted in
hypoglycosylation of pCatC. The differences between
OSTs harboring Stt3-A or Stt3-B were described more
specifically when looking at individual glycosylation sites
in defined substrates: Stt3-B was found to act preferentially
on sites glycosylated posttranslationally, whereas Stt3-A
catalyzed cotranslational glycosylation. Such a sequential
action of the OST complexes with Stt3-A and Stt3-B was
demonstrated for the glycosylation process of two different
glycoproteins (Ruiz-Canada et al. 2009). Therefore, the
different OST forms (containing either Stt3-A or Stt3-B)
differ with respect to substrate specificity as well as in the
temporal order in the processing of polypeptides entering
the lumen of the ER.
Ribophorin I
Ribophorin I and II and OST48 were the first identified
subunits of the mammalian OST complex, which was
purified from canine pancreas (Kelleher et al. 1992). Initial
data suggested a catalytic glycosyltransferase activity for
ribophorin I, but subsequent studies clearly assigned this
function to the Stt3 subunits (Nilsson et al. 2003; Yan and
Lennarz 2002). Ribophorin I is highly conserved among
various species, and human ribophorin shares >90%
sequence identity with homologous proteins in vertebrates.
It is a 68-kDa type-I transmembrane protein with a single,
predicted transmembrane helix; a large, luminal domain;
and a smaller, C-terminal cytosolic domain. Ribophorins
are highly abundant ER proteins, exclusively present in the
rough ER in about equal amounts relative to membrane-
bound ribosomes (Kreibich et al. 1978c; Marcantonio et al.
1984). Direct interactions between ribophorins and ribo-
somes were detected in cross-linking experiments, and
therefore, the cytoplasmically oriented parts of ribophorins
were considered to provide binding sites for translating
ribosomes (Kreibich et al. 1978a; Kreibich et al. 1978b).
Indeed, antibodies against the C-terminal cytosolic domain
of ribophorin I prevent ribosome targeting to the ER
membrane by blocking ribosome association to the trans-
location channel, and they inhibit protein translocation (Yu
et al. 1990). Ribophorin I and ribophorin II were also
detected in ribosome fractions isolated from native ER
membranes (Gorlich et al. 1992; Menetret et al. 2000;
Wang and Dobberstein 1999). In summary, these data
provide solid experimental evidence that at least a subset of
OST complexes in the ER are associated with the trans-
locon (Shibatani et al. 2005), enabling cotranslocational
glycosylation of entering polypeptides.
Ribophorin I is not essential for glycosylation per se
but, rather, affects utilization of certain glycosylation sites
on defined polypeptides (Wilson and High 2007). Single-
spanning membrane proteins required ribophorin I expres-
sion for efficient glycosylation, but glycosylation of
secretory proteins (α1-antitrypsin, transferrin, and tyrosi-
nase) and multispanning membrane proteins was not
affected by ribophorin I depletion (Wilson et al. 2008). A
chaperone-like activity of ribophorin I was proposed in the
case of the substrate mu-opioid receptor (MOR), a member
of the G-protein-coupled receptor family. Direct interac-
tions between MOR and ribophorin I were shown by
coimmunoprecipitation when His-tagged MOR was puri-
fied from neuroblastoma cells. MOR receptor trafficking
and surface expression is regulated via glycosylation of the
MOR receptor. Ribophorin I overexpression rescued
surface expression of intracellular retained MOR variants,
but N-linked glycosylation-deficient variants were not
rescued by ribophorin I overexpression (Ge et al. 2009).
Ribophorin II
Ribophorin II is highly conserved in mammals; the human
ribophorin II shares >90% sequence identity with ribo-
phorin II from mice, rat, and pig. Primary structure analysis
suggests a large N-terminal luminal domain followed by a
hydrophobic transmembrane domain with three predicted
α-helices and a small C-terminal segment located in the
cytoplasm (Crimaudo et al. 1987). ER localization of
ribophorin II is mediated by independent ER retention
signals located in the transmembrane segment and cytosolic
part. A 15 amino acid residue luminal region strengthens
ER localization, but no defined ER retention signals were
found in the ER luminal part (Fu et al. 2000).
Ribophorin II expression is elevated in drug-resistant
human breast cancer cells (Honma et al. 2008). Down-
regulation of ribophorin II restores docetaxel-induced
apoptosis in drug-resistant human breast cancer cells, and
in vivo delivery of ribophorin II siRNA reduced tumor
growth in drug-resistant tumor types. Here, ribophorin II-
mediated drug resistance is regulated via P-glycoprotein
glycosylation. The general reduction of N-linked glycosyl-
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ation by ribophorin II downregulation also leads to
hypoglycoylation of P-glycoprotein and results in functional
inactivity. P-glycoprotein is a key player in conferring drug
resistance, and stable membrane-bound P-glycoprotein
requires complete glycosylation (Honma et al. 2008).
OST 48
OST48, the third initially identified OST subunit, was
copurified with active canine OST (Kelleher et al. 1992).
Canine OST48 and yeast Wbp1, an essential subunit of the
yeast OST complex, share 25% sequence identity (Silberstein
et al. 1992). OST48 is, however, highly conserved
in mammals. The human OST48 subunit shares >90%
sequence identity with other mammalian OST48 proteins.
Human OST48 consists of 456 residues; the first 42 are
suggested to include a signal sequence, followed by a large,
lumen-oriented domain. One single transmembrane span
constitutes OST48 as type I membrane protein with a very
small C-terminal cytosolic segment comprising only nine
residues. The C-terminal cytosolic domain of canine
OST48 was shown to interact with DAD1, another
component of OST, and interactions between the luminal
domain of OST48 and ribophorin I were detected by yeast
two-hybrid screening and in vitro binding assays. Interest-
ingly, OST48 seems to provide a link between ribophorin I
and ribophorin II in the active OST complex, as the N-
terminal luminal domain of OST48 interacts with the
luminal domain of ribophorin I and ribophorin II, but a
direct interaction between ribophorin I and ribophorin II
was not observed (Fu et al. 1997).
Pig OST48 contains a double lysine motif at the very C-
terminus, which was suggested to confer ER residency
(Hardt et al. 2000; Hardt et al. 2001). Replacing the lysine
motif by leucine residues elicits cell-surface expression of
the OST48 mutant protein. However, cell-surface localiza-
tion was abolished by ribophorin I overexpression, indicat-
ing a direct interaction between OST48 and ribophorin I.
The yeast homolog Wbp1p contains a similar dilysine motif
that functions as an ER retrieval signal (Gaynor et al.
1994). The yeast Wbp1p was proposed to be responsible
for binding of the lipid-linked oligosaccharide donor
substrate (Pathak et al. 1995), but further experimental
evidence to support this notion is missing.
DAD1
DAD1 (defender against apoptotic cell death), was initially
discovered in the search for genes involved in apoptosis.
The apoptotic phenotype of a temperature-sensitive cell line
at nonpermissive temperature was rescued by human
DAD1, and apoptosis was induced by degradation of the
mutated DAD1 protein at nonpermissive temperatures
(Nakashima et al. 1993). DAD1 is the most conserved
OST subunit: canine, bovine, and human DAD1 share 99%
sequence identity; and human, mice, rat, and hamster
DAD1 proteins are identical. Human DAD1 is a small,
113-residue polypeptide with two predicted transmembrane
span helices in the center of the protein and both termini
located in the cytosol.
Analysis of the canine OST complex revealed a tight
association of DAD1 with the active OST complex
(Kelleher and Gilmore 1997). Moreover, specific interac-
tions between the amino terminal domain of DAD1 and
OST48 were reported (Fu et al. 1997). The instability of the
temperature-sensitive DAD1 mutant at restrictive tempera-
ture causes a time-dependent degradation of the other OST
subunits ribophorin I, ribophorin II, and OST48, disrupting
the entire OST complex (Sanjay et al. 1998). Consequently,
the loss of OST activity caused by DAD1 instability results
in severe hypoglycosylation that might induce apoptosis
(Makishima et al. 1997; Sanjay et al. 1998).
Interestingly, OST activity was retained in dad1 null (−/−)
mice blastocytes (Nishii et al. 1999) but hypoglycosylation
of specific glycoproteins was detected (Hong et al. 2000).
This observation is in agreement with other data suggesting
that N-linked glycosylation is not required in very early
embryonic stages but becomes essential at later develop-
mental stages (Surani 1979). DAD1 might provide structural
and functional integrity for the OST complex, and a
deficiency causes a time-dependent defect on OST activity
(Sanjay et al. 1998). Heterozygous dad1 (+/−) mice are
viable and display no severe abnormalities but rather mild
forms of thymic hypoplasia and soft tissue syndactyly
(Brewster et al. 2000; Hong et al. 2000; Nishii et al. 1999).
N33/Tusc3 and IAP
N33/Tusc3 and IAP are two paralogous, mutually exclusive
subunits of the mammalian OST complex. Human N33/
Tusc3 and IAP share 70% sequence identity with similar
predicted membrane topology, consisting of an N-terminal
luminal domain including approximately 170 residues,
followed by a transmembrane domain with four transmem-
brane segments. The full-length human N33/Tusc3 poly-
peptide contains 348 residues, and IAP consists of 335
residues. Both proteins contain an N-terminal signal sequence,
which is very likely to be cleaved off after translocation.
Human N33/Tusc3 exists in two splicing variants, differing
from each other only in the last five residues. Splicing variant
1, N33-1 cosedimented with the active OST complex, but
N33-2 and IAP dissociated from the OST complex during
membrane solubilization and are most likely weakly associ-
ated with the active complex (Kelleher et al. 2003).
N33/Tusc3 was initially described as tumor suppressor
candidate (MacGrogan et al. 1996) based on the location of its
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gene on the short arm of chromosome 8. This region is
frequently lost in various tumor cells. Normal expression
levels of N33/Tusc3 were observed in various tissues,
including heart, brain, lung, liver, placenta, pancreas, prostate,
testis, and colon (Kelleher et al. 2003; MacGrogan et al.
1996), but expression was downregulated in many colorectal,
lung, liver, breast, and pancreatic cancer cell lines (Bashyam
et al. 2005; Cooke et al. 2008; MacGrogan et al. 1996).
Based on sequence similarity and secondary structure
prediction, N33/Tusc3 and IAP are homologous to the yeast
OST subunits OST3p and OST6p, respectively. Recent
structural and biochemical studies on the luminal domain of
the yeast OST6p showed a thioredoxin-like fold for the
luminal domain and revealed oxidoreductase activity for this
domain (Schulz et al. 2009). Based on sequence similarity,
N33/Tusc3 and IAP are proposed to have oxidoreductase
activity as well (Fetrow et al. 2001). Though this is the
functionally best characterized subunit of eukaryotic OST
complexes, there are conflicting results regarding the role of
these proteins in vivo. Zhou and coworkers suggest that N33/
Tusc3 and IAP might be involved in magnesium homeostasis
(Zhou and Clapham 2009). Most interestingly, deficiency of
human N33/Tusc3 or IAP results in isolated cognitive defects
(Garshasbi et al. 2008; Molinari et al. 2008) (see below).
OST4
The subunit OST4 is a 37-residue peptide with a single
transmembrane helix. Its association with the mammalian
OST complex was proposed based on sequence similarity to
the yeast OST4p subunit of OST, and OST4 has also been
identified as a component of the purified canine OST
complex (Kelleher and Gilmore 2006).
Human OST4 contains a very short luminal segment with
one transmembrane span followed by a cytoplasmic part
consisting of approximately ten residues. Besides the high
conservation among mammalian species, reflected in 100%
sequence identity between human, rat, and mice OST4, very
little is known about the function of mammalian OST4. In the
yeast OST complex, OST4p regulates the incorporation of the
two functionally equivalent, but mutually exclusive, subunits
OST3p and OST6p (Spirig et al. 2005). Single-point
mutations in the transmembrane segment of OST4p disrupt
the interaction between OST4p, OST3p, and Stt3p, causing
severe growth defects in yeast (Kim et al. 2000; Kim et al.
2003).
Human diseases associated with OST
The high substrate specificity of the OST complex with
respect to the structure of the lipid-linked oligosaccharide is
responsible for the very often severe phenotypes of many of
the congenital disorders of glycosylation (CDG) type I.
However, only few cases where OST activity is affected
directly are known so far. It can be assumed that most
mutations affecting the central components of OST, such as
the Stt3 proteins, can have lethal affects in a homozygous
situation. It is therefore not surprising that the known cases
affect the mutually exclusive paralogs N33/Tusc3 and IAP.
Based on genetic evidence, homozygous loss of function
mutations in N33/Tusc3 or IAP result in nonsyndromic
mental retardation (Garshasbi et al. 2008; Molinari et al.
2008). Interestingly, this specific symptom of the disease
is in sharp contrast to the pleiotropic affects induced by
mutations altering LLO substrate biosynthesis, and the
CDG-typical hypoglycosylation of the marker protein
transferrin is not observed in these patients. More
generally, serum N-glycome, as analyzed by mass spec-
trometry, showed neither quantitative nor qualitative
differences in these patients. These observations are in
line with the functional analysis of the homologous OST
subunits in yeast that point to their role in efficient
glycosylation of defined polypeptide substrates by alter-
ing the kinetics of their oxidative folding (Schulz et al.
2009). Within the framework of this hypothesis, N33/
Tusc3 and IAP might ensure defined glycosylation of a
subset of proteins that are required for normal brain
development.
A polymorphism in the ribophorin II locus has recently
been detected in a screen for mutations occurring in 27
CDG-patients without clear diagnosis at a molecular
level. The G374D missense mutation lies in the second
half of the N-terminal luminal domain of ribophorin II.
Interestingly, the affected patient presents a fairly mild
clinical phenotype, but a clear genotype–phenotype
correlation for this mutation could not be established
(Vleugels et al. 2009).
Outlook
OST is the key player in transferring the glycan onto the
selected glycosylation sequons present in many different
substrates. The N-linked glycans perform a multitude of
functions at a cellular and organismal level. Alterations
in the biosynthesis of the unique lipid-linked oligosac-
charide substrate of OST therefore affect the glycosyla-
tion efficiency and functionality of many different
proteins and results in a highly diverse set of symptoms
that characterize CDG-type I patients. In contrast, the
recent identification of deficiencies in OST activity that
result in highly specific clinical pictures suggests that
mutations affecting the selection of a subset of polypep-
tide substrates by OST can yield a more defined and less
general phenotype. However, it is difficult to predict the
J Inherit Metab Dis (2011) 34:869–878 875
clinical pictures that might emerge from OST complexes
containing a certain mutant subunits. Our knowledge
about the function of these subunits in the N-glycosylation
process is limited and does not allow predictions for
diagnosis. In addition, our tools to analyze the N-linked
protein glycosylation pathway are limited. We have to be
aware that the output of the N-glycosylation process is a
large number of different N-glycoproteins, and the exact
description of this output requires quantitation of the site
occupancy at every potential N-glycosylation site. This is
a typical problem addressed by analytical approaches at a
systemic level, and a first step toward the quantitative
description of the N-glycoproteome in eukaryotes has
recently been published (Zielinska et al. 2010). It is
evident that the quantitative description of the N-
glycoproteome as a diagnostic tool will lead to identification
of mutations that affect polypeptide substrate selection of
OST directly. Alternatively, whole-genome sequencing of
patient DNA will reveal OST mutations, and the
subsequent characterization of the N-glycoproteome will
provide additional information to define the molecular
function of the different OST components. Eventually,
this understanding of OST-mediated catalysis will open
the way for the development of drugs that affect the
properties of the enzyme. Altering lipid-linked substrate
specificity might reduce many of the severe symptoms
observed in patients with the different types of CDG-I.
To reach this long-term goal, we have to understand the
function of a unique enzyme, OST, which modulates the
activity of a large number of different proteins and
which is of central importance for the generation of the
eukaryotic glycome.
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